AFC Gamma Inc. (AFCG) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
477 S. ROSEMARY AVE., SUITE 301 WEST PALM BEACH, FL 33401 |
| State of Incorp. | MD |
| Fiscal Year End | December 31 |
| Industry (SIC) | 65 - Real Estate (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 9/30/2024 MRQ | 12/31/2023 | 12/31/2022 | 12/31/2021 | |||
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Current Assets | ||||||
| Cash, cash equivalents, and short-term investments | 121,626 | 140,373 | 109,246 | |||
| Cash and cash equivalents | 121,626 | 140,373 | 109,246 | |||
| Total current assets: | 121,626 | 140,373 | 109,246 | |||
| Noncurrent Assets | ||||||
| Other undisclosed assets | 344,959 | 378,804 | 355,602 | |||
| TOTAL ASSETS: | 466,585 | 519,177 | 464,848 | |||
| LIABILITIES AND EQUITY | ||||||
| Liabilities | ||||||
| Current Liabilities | ||||||
| Noncurrent Liabilities | ||||||
| Other undisclosed liabilities | 146,533 | 180,118 | 191,773 | |||
| Total liabilities: | 146,533 | 180,118 | 191,773 | |||
| Equity | ||||||
| Equity, attributable to parent | 320,052 | 339,059 | 273,075 | |||
| Preferred stock | 0 | 0 | 0 | |||
| Common stock | 205 | 204 | 164 | |||
| Additional paid in capital | 349,806 | 348,818 | 274,173 | |||
| Accumulated other comprehensive loss | (169) | |||||
| Accumulated deficit | (29,958) | (9,962) | (1,093) | |||
| Total equity: | 320,052 | 339,059 | 273,075 | |||
| TOTAL LIABILITIES AND EQUITY: | 466,585 | 519,177 | 464,848 | |||
Income Statement (P&L) ($ in thousands)
| 9/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|---|---|
| Revenues | 64,178 | 450 | 450 | ||
| Realized investment gains (losses) | (1,340) | 450 | 450 | ||
| Cost of revenue (Provision for Loan, Lease, and Other Losses) | (12,133) | (11,177) | (2,649) | ||
| Gross profit: | 52,045 | (10,727) | (2,199) | ||
| Operating expenses | (21,566) | (23,405) | (14,398) | ||
| Operating income (loss): | 30,479 | (34,133) | (16,598) | ||
| Nonoperating income (Investment Income, Nonoperating) | 64,178 | 81,499 | 38,140 | ||
| Interest and debt expense | 1,986 | (6,814) | (1,127) | ||
| Income from continuing operations before equity method investments, income taxes: | 96,643 | 40,552 | 20,416 | ||
| Other undisclosed income (loss) from continuing operations before income taxes | (74,031) | (3,593) | 620 | ||
| Income from continuing operations before income taxes: | 22,611 | 36,959 | 21,036 | ||
| Income tax expense | (1,659) | (1,026) | (35) | ||
| Income from continuing operations: | 20,952 | 35,932 | 21,000 | ||
| Income before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | 21,000 | |
| Income from discontinued operations | |||||
| Net income attributable to parent: | 20,952 | 35,932 | 21,000 | ||
| Preferred stock dividends and other adjustments | (15) | (15) | |||
| Other undisclosed net loss available to common stockholders, basic | (262) | ||||
| Net income available to common stockholders, basic: | 20,675 | 35,917 | 21,000 | ||
| Dilutive securities, effect on basic earnings per share | (135) | ||||
| Net income available to common stockholders, diluted: | 20,675 | 35,782 | 21,000 | ||
Comprehensive Income ($ in thousands)
| 9/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|---|---|
| Net income: | 20,952 | 35,932 | 21,000 | ||
| Comprehensive income: | 20,952 | 35,932 | 21,000 | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | 169 | (169) | |||
| Comprehensive income, net of tax, attributable to parent: | 20,952 | 36,101 | 20,832 | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.